Decrease in circulating autotaxin by oral administration of prednisolone

Clinica Chimica Acta

Volumn 415, Issue , 2013, Pages 74-80

  Sumida, Hayakazu ^a   Nakamura, Kazuhiro ^b   Yanagida, Keisuke ^a   Ohkawa, Ryunosuke ^b   Asano, Yoshihide ^a   Kadono, Takafumi ^a   Tamaki, Kunihiko ^a   Igarashi, Koji ^c   Aoki, Junken ^d   Sato, Shinichi ^a   Ishii, Satoshi ^a   Shimizu, Takao ^a   Yatomi, Yutaka ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOSOH CORPORATION   (Japan)

^d TOHOKU UNIVERSITY   (Japan)

Author keywords

Autotaxin (ATX); Lysophosphatidic acid (LPA); Lysophospholipase D (LysoPLD); Lysophospholipid; Prednisolone (PSL)

Indexed keywords

AUTOTAXIN; BETAMETHASONE; BIOLOGICAL MARKER; CHOLINE; LYSOPHOSPHATIDYLCHOLINE; LYSOPHOSPHOLIPASE; MESSENGER RNA; PREDNISOLONE;

ADIPOSE TISSUE; ANIMAL TISSUE; ARTICLE; AUTOTAXIN GENE; CLINICAL ARTICLE; COLLAGEN DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DOWN REGULATION; DRUG DOSE REDUCTION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME IMMUNOASSAY; FEMALE; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADIPOSE TISSUE; ADMINISTRATION, ORAL; ANIMALS; AUTOIMMUNE DISEASES; BIOMARKERS, PHARMACOLOGICAL; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; GLUCOCORTICOIDS; HUMANS; IMMUNOENZYME TECHNIQUES; LYSOPHOSPHATIDYLCHOLINES; LYSOPHOSPHOLIPIDS; MALE; MICE; MICE, INBRED C57BL; PHOSPHORIC DIESTER HYDROLASES; PREDNISOLONE; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE CULTURE TECHNIQUES;

MURINAE; MUS;

EID: 84868230143     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.10.003     Document Type: Article

References (42)

1. Tokumura A. A family of phospholipid autacoids: occurrence, metabolism and bioactions. Prog Lipid Res 1995, 34:151-184.
2. Anliker B., Chun J. Lysophospholipid G protein-coupled receptors. J Biol Chem 2004, 279:20555-20558.
3. Sumida H., Noguchi K., Kihara Y., et al. LPA4 regulates blood and lymphatic vessel formation during mouse embryogenesis. Blood 2010, 116:5060-5070.
4. Chun J., Hla T., Lynch K.R., Spiegel S., Moolenaar W.H., International Union of Basic and Clinical Pharmacology LXXVIII Lysophospholipid receptor nomenclature. Pharmacol Rev 2010, 62:579-587.
5. Yanagida K., Ishii S. Non-Edg family LPA receptors: the cutting edge of LPA research. J Biochem 2011, 150:223-232.
6. Tanaka M., Okudaira S., Kishi Y., et al. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem 2006, 281:25822-25830.
7. van Meeteren L.A., Ruurs P., Stortelers C., et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol 2006, 26:5015-5022.
8. Stracke M.L., Krutzsch H.C., Unsworth E.J., et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 1992, 267:2524-2529.
9. Giganti A., Rodriguez M., Fould B., et al. Murine and human autotaxin alpha, beta, and gamma isoforms: gene organization, tissue distribution, and biochemical characterization. J Biol Chem 2008, 283:7776-7789.
10. Lee H.Y., Murata J., Clair T., et al. Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells. Biochem Biophys Res Commun 1996, 218:714-719.
11. Kishi Y., Okudaira S., Tanaka M., et al. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem 2006, 281:17492-17500.
12. Zhao H., Ramos C.F., Brooks J.D., Peehl D.M. Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues. J Cell Physiol 2007, 210:111-121.
13. Moolenaar W.H., Perrakis A. Insights into autotaxin: how to produce and present a lipid mediator. Nat Rev Mol Cell Biol 2011, 12:674-679.
14. Koike S., Keino-Masu K., Ohto T., Sugiyama F., Takahashi S., Masu M. Autotaxin/lysophospholipase D-mediated lysophosphatidic acid signaling is required to form distinctive large lysosomes in the visceral endoderm cells of the mouse yolk sac. J Biol Chem 2009, 284:33561-33570.
15. Moolenaar W.H., van Meeteren L.A., Giepmans B.N. The ins and outs of lysophosphatidic acid signaling. Bioessays 2004, 26:870-881.
16. Nakamura K., Kishimoto T., Ohkawa R., et al. Suppression of lysophosphatidic acid and lysophosphatidylcholine formation in the plasma in vitro: proposal of a plasma sample preparation method for laboratory testing of these lipids. Anal Biochem 2007, 367:20-27.
17. Umezu-Goto M., Kishi Y., Taira A., et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 2002, 158:227-233.
18. Nakamura K., Takeuchi T., Ohkawa R., et al. Serum lysophospholipase D/autotaxin may be a new nutritional assessment marker: study on prostate cancer patients. Ann Clin Biochem 2007, 44:549-556.
19. Tsuda S., Okudaira S., Moriya-Ito K., et al. Cyclic phosphatidic acid is produced by autotaxin in blood. J Biol Chem 2006, 281:26081-26088.
20. Watanabe N., Ikeda H., Nakamura K., et al. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J Clin Gastroenterol 2007, 41:616-623.
21. Watanabe N., Ikeda H., Nakamura K., et al. Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity. Life Sci 2007, 81:1009-1015.
22. Nakamura K., Igarashi K., Ide K., et al. Validation of an autotaxin enzyme immunoassay in human serum samples and its application to hypoalbuminemia differentiation. Clin Chim Acta 2008, 388:51-58.
23. Nakamura K., Nangaku M., Ohkawa R., et al. Analysis of serum and urinary lysophospholipase D/autotaxin in nephrotic syndrome. Clin Chem Lab Med 2008, 46:150-151.
24. Masuda A., Nakamura K., Izutsu K., et al. Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma. Br J Haematol 2008, 143:60-70.
25. Nakai Y., Ikeda H., Nakamura K., et al. Specific increase in serum autotaxin activity in patients with pancreatic cancer. Clin Biochem 2011, 44:576-581.
26. Nakagawa H., Ikeda H., Nakamura K., et al. Autotaxin as a novel serum marker of liver fibrosis. Clin Chim Acta 2011, 412:1201-1206.
27. Masuda A., Fujii T., Iwasawa Y., et al. Serum autotaxin measurements in pregnant women: application for the differentiation of normal pregnancy and pregnancy-induced hypertension. Clin Chim Acta 2011, 412(21-22):1944-1950.
28. Viguerie N., Millet L., Avizou S., Vidal H., Larrouy D., Langin D. Regulation of human adipocyte gene expression by thyroid hormone. J Clin Endocrinol Metab 2002, 87:630-634.
29. Demozay D., Rocchi S., Mas J.C., et al. Fatty aldehyde dehydrogenase: potential role in oxidative stress protection and regulation of its gene expression by insulin. J Biol Chem 2004, 279:6261-6270.
30. Ferry G., Tellier E., Try A., et al. Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. J Biol Chem 2003, 278:18162-18169.
31. Dusaulcy R., Rancoule C., Gres S., et al. Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid. J Lipid Res 2011, 52:1247-1255.
32. de Oliveira C., de Mattos A.B., Biz C., Oyama L.M., Ribeiro E.B., do Nascimento C.M. High-fat diet and glucocorticoid treatment cause hyperglycemia associated with adiponectin receptor alterations. Lipids Health Dis 2011, 10:11.
33. Ahima R.S., Flier J.S. Leptin. Annu Rev Physiol 2000, 62:413-437.
34. Sugimoto S., Sugimoto H., Aoyama C., Aso C., Mori M., Izumi T. Purification and characterization of lysophospholipase D from rat brain. Biochim Biophys Acta 2006, 1761:1410-1418.
35. Jansen S., Andries M., Vekemans K., Vanbilloen H., Verbruggen A., Bollen M. Rapid clearance of the circulating metastatic factor autotaxin by the scavenger receptors of liver sinusoidal endothelial cells. Cancer Lett 2009, 284:216-221.
36. Albers H.M., Dong A., van Meeteren L.A., et al. Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc Natl Acad Sci U S A 2010, 107:7257-7262.
37. Nakasaki T., Tanaka T., Okudaira S., et al. Involvement of the lysophosphatidic acid-generating enzyme autotaxin in lymphocyte-endothelial cell interactions. Am J Pathol 2008, 173:1566-1576.
38. Kanda H., Newton R., Klein R., Morita Y., Gunn M.D., Rosen S.D. Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs. Nat Immunol 2008, 9:415-423.
39. Tager A.M., LaCamera P., Shea B.S., et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 2008, 14:45-54.
40. Castelino F.V., Seiders J., Bain G., et al. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. Arthritis Rheum 2011, 63:1405-1415.
41. Pradere J.P., Klein J., Gres S., et al. LPA1 receptor activation promotes renal interstitial fibrosis. J Am Soc Nephrol 2007, 18:3110-3118.
42. Tokumura A., Carbone L.D., Yoshioka Y., et al. Elevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis. Int J Med Sci 2009, 6:168-176.